Navigation Links
Agendia Appoints New CEO and Supervisory Board Member
Date:10/24/2011

IRVINE, California and AMSTERDAM, October 24, 2011 /PRNewswire/ --

Agendia, an innovative molecular diagnostics company, today announced that its supervisory board of directors has appointed David Macdonald as chief executive officer. This follows the resignation of the company's co-founder and chief executive officer, Dr. Bernhard Sixt. Dr. Sixt will remain with the company in an advisory capacity. Agendia also announced the addition of Dr. Colin Goddard, executive chairman and acting CEO of privately held biotechnology firm Coferon, Inc., to its supervisory board of directors.

"On behalf of Agendia's board and all its employees, I would like to personally extend my deepest gratitude to Dr. Sixt for his leadership in making this company an internationally recognized innovator in the molecular diagnostic space," said Hessel Lindenbergh, chairman of Agendia's supervisory board. "David Macdonald is an accomplished leader in our industry and I have no doubt that under his leadership, Agendia will continue to thrive."

Macdonald has served as Agendia's COO since April 2010 and brings with him more than 25 years of international experience developing and commercializing clinical diagnostics and laboratory services for companies including Nova Biomedical, Behring Diagnostics, Nichols Institute and Quest Diagnostics. He has held CEO and COO roles for the past 18 years. He holds a Bachelor of Science degree from Northeastern University in management and finance as well as an MBA from Babson College.

Dr. Goddard served as CEO of OSI Pharmaceuticals, Inc. and as a member of the company's board of directors until it's $4 billion acquisition by Astellas Pharmaceuticals, Inc. in July of 2010. He currently serves as executive chairman and acting CEO of Coferon, Inc., a privately held biotechnology platform company. He is also a director of biotechnology companies PanOptica and Human Genome Sciences, Inc. Dr. Goddard is actively involved as an advisor to several venture capital firms and other industry groups.

"I'm pleased to welcome Collin Goddard to our supervisory board of directors. He brings with him a wealth of knowledge in the biotechnology sector and will be an asset to Agendia moving forward," said Lindenbergh.

About Agendia:

Agendia is an international molecular diagnostic company, focused on the discovery and development of tools to improve the quality of life for cancer patients, by providing healthcare professionals with critical information that enables personalized treatment.   Agendia's Symphony™ suite of breast cancer products is based on genomic analysis of an individual patient's tumor biology, providing unprecedented insight for complex treatment decisions. Symphony includes MammaPrint, the first and only FDA-cleared breast cancer recurrence assay, as well as BluePrint, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and which patients do not require these treatments and can instead be treated with other less arduous and costly methods. For additional information, please visit http://www.agendia.com.


'/>"/>
SOURCE Agendia B.V.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Launches TargetPrint(R) for Breast Cancer Patients
2. Agendias MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
3. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
4. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
5. Agendias Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
6. Agendias Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
7. /C O R R E C T I O N -- Agendia B.V./
8. FDA Broadens Clearance for Agendias MammaPrint(R)
9. Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer
10. Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests
11. Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... JERUSALEM , Sept. 5, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage pharmaceutical company focused on the ... it has successfully concluded its meeting with the U.S. ... novel oral insulin formulation. ... that the regulatory pathway for submission of ORMD-0801, would ...
(Date:9/1/2017)... 2017  Explorers Like Us ( https://explorerslikeus.com/ ) is embarking ... — and deliver these experiences as part of Life Environments™, ... and heal better. ... While nothing beats a walk, jog or simply playing ... Environments™ is the next best thing when getting there isn’t ...
(Date:8/31/2017)... 2017 PM360,s annual Innovations Issue, published ... latest innovations happening across the industry. Established six years ... on providing a comprehensive look at the newest and ... most innovative companies, startups, divisions, products, services, and strategies ... "Everyone in this industry wants to do better—in ...
Breaking Medicine Technology:
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... METTLER TOLEDO ... place October 25-26, 2017 in Los Angeles, CA. The symposium will feature speakers from ... dealing with today's mass calibration technologies and help with planning for the future of ...
(Date:9/25/2017)... ... September 25, 2017 , ... The Asset Tracking and Temperature ... is as simple as scanning the bar code of the product and lot ID ... secure internet cloud where violations are automatically generated and exception alerts sent out to ...
(Date:9/25/2017)... York, NY (PRWEB) , ... September 25, 2017 ... ... , explained why retirement is not an option to senior, upper-level executives speaking ... savings account." , "A senior, high-level executive is an asset to be ...
(Date:9/25/2017)... ... September 25, 2017 , ... Earlypicker is expanding its offerings ... shop for the hottest Korean cosmetics and fashion trends sweeping the nation. The decision ... already well-known for the great offerings that allow Koreans everywhere to look their best ...
(Date:9/25/2017)... ... ... “Renew Refresh Restore Reward”: is a story of struggle and how trouble often happens ... Freeman, cofounded the Free Spirit Bible Church and currently serves as the church’s Director ... us to come over before the baby had to go back to her grandparents. ...
Breaking Medicine News(10 mins):